2E9 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EST
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€41.01M
Enterprise Value€301.20M
Total Cash (Recent Filing)€145.63M
Total Debt (Recent Filing)€357.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.44M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseA low-debt, high-equity balance sheet gives Intervacc durable financial flexibility to fund R&D, regulatory work and commercialization despite losses. This capital buffer reduces near-term insolvency risk, limits forced dilution and supports multi-quarter runway to execute strategic initiatives.
Commercialized Flagship VaccineHaving an approved, commercial product (Strangvac) establishes a recurring revenue stream and real-world market access. This durable asset validates the platform, supports distribution partnerships, and creates a base for incremental sales, label expansions and partner-led geographic rollouts over months.
Improving Free Cash Flow TrendA sizable improvement in FCF growth signals operational progress—either higher sales or better cost control—which, if sustained, reduces reliance on external funding. This trend, even from negative to less-negative, materially extends runway and improves chances of reaching self-funding status over several quarters.
Bears Say
Heavy Cash BurnSustained large negative operating and free cash flows will erode equity and force frequent external financing if not reversed. Over months this constrains discretionary spending, risks program delays, and increases dilution or debt issuance risk, limiting strategic freedom and long-term execution.
Deep Operating Losses / Negative MarginsExtremely negative gross and operating margins indicate the current business model is not covering costs. Without structural margin improvement—through pricing, cost reductions, or higher volume—losses will persist, undermining profitability prospects and making sustainable growth difficult.
Modest, Recently Declining Revenue BaseA small revenue base that has recently declined limits scale economies and makes fixed costs harder to absorb. Over 2-6 months this constrains margin recovery, reduces bargaining power with distributors, and heightens dependence on a single product's adoption trajectory for any meaningful financial turnaround.
Intervacc AB News
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €41.01M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -6.494%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―